Versarien subsidiary reports "major advance" in graphene platelet production
11th Jun 2015 09:18
Materials engineering firm Versarien jumped after announcing that its graphene development subsidiary, 2-DTech, has made a "major" advance in graphene platelet production, which it believes will accelerate potential commercial applications for graphene and graphene products. It has developed its own
Read moreVersarien purchases graphene specialist, placing oversubscribed
14th Apr 2014 11:18
Advanced engineering materials group Versarien has agreed on the terms for the purchase of 2-DTech from The University of Manchester for a total consideration of £440,000 in cash and ordinary shares. 2-DTech specialises in the supply, characterisation and early stage development of graphene produc
Read moreVersarien predicts second half performance to be in line with first
19th Mar 2014 13:04
Versarien, an AIM-listed engineering materials company, has said its second half results will be in line with the first and revealed the first commercial contract signing for its Versarien Technologies (VTL) division. The group said that its results for the second half of the year to March 31st 20
Read moreWednesday broker round-up UPDATE
19th Mar 2014 09:00
Afren: Canaccord Genuity lowers target price from 185p to 180p and stays with its buy recommendation. Antofagasta: Westhouse Securities reduces target price from 1060p to 985p staying with its buy recommendation. Credit Suisse downgrades from neutral to underperform with a target price of 750p. JP
Read moreTuesday broker round-up UPDATE
3rd Dec 2013 09:10
Arrow Global: Numis starts with a target price of 270p and an add rating. Antofagasta: UBS shaves target price from 870p to 845p, 'neutral' rating maintained. Aquarius Platinum: UBS cuts target price from 44p to 43p, 'neutral' rating kept. Ashtead Group: Citi raises target price from 750p to 800p
Read moreFriday broker round-up UPDATE
27th Sep 2013 08:48
Admiral Group: Berenberg ups target price from 1060p to 1080p, but still recommends selling. Amlin: Berenberg reduces target price from 422p to 398p and downgrades to sell. Atkins (WS): JP Morgan increases target price from 1298p to 1348p and maintains an overweight rating. AZ Electronic Material
Read moreFriday broker round-up UPDATE
12th Jul 2013 08:11
Ashmore Group: Morgan Stanley cuts target price from 444p to 420p and leaves its equal-weight rating unchanged. JP Morgan ups target price from 339p to 377p maintaining a neutral rating. AstraZeneca: Jefferies reduces target price from 3560p to 3400p, while keeping its hold recommendation. Aviva:
Read more